Cross-Sector entity
Wall Street Zen is most often covered alongside Weiss Ratings, which appears in 18 of these 20 stories. The 12-day window averages about 11.7 stories each week. The busiest single day carried 5. Coverage clusters in earnings, which accounts for 5 of those 20, with the remainder spread across 7 other categories.
93 verified stories tracked
Last mentioned: 14h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Wall Street Zen is most often covered alongside Weiss Ratings, which appears in 18 of these 20 stories. The 12-day window averages about 11.7 stories each week. The busiest single day carried 5. Coverage clusters in earnings, which accounts for 5 of those 20, with the remainder spread across 7 other categories. The tracked stories average 2 original sources each. 0% of these stories carry negative sentiment. We currently track 20 Cross-Sector stories that mention Wall Street Zen, published between August 13, 2026 and August 24, 2026.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wall Street Zen. Shared-story counts are live from our verified record — not editorial picks.
Dividend payment
The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Ex-dividend date
Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Enveric reports quarterly loss
Enveric Biosciences reported EPS of -$0.76 for the quarter.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Benchmark cuts BKKT target
Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
Insider sales
CEO Sushil Patel sold 39,341 shares at $12.97 and insider Konstantinos Xynos sold 11,447 shares at $12.97, both to cover tax withholding obligations.
Bakkt reports quarterly results
Bakkt announced EPS of $1.94 and revenue of $170.15 million, missing revenue consensus of $373.27 million.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
Wedbush upgrade
Wedbush upgraded Replimune Group from neutral to outperform and set a $12.00 price target.
Cantor Fitzgerald raises DEI target
Cantor Fitzgerald raised its Douglas Emmett target price from $12.00 to $13.00 with a neutral rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Applied Digital's 8.6% drop to $28.51, paired with a 5.1% fall in quantum peer Rigetti, signals cooling sentiment toward AI-adjacent infrastructure stocks after APLD's July earnings miss. High beta and negative EPS are forcing AI investors to reassess execution risk.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Crypto platform Bakkt's sell-to-hold upgrade masks a brutal year: shares at $7.66 are down 85% from $49.79. A director's insider buy and an extreme beta of 5.91 frame the risk-reward for Web3 investors watching custody and exchange infrastructure.
Source: tickerreport.com · themarketsdaily.com
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Replimune missed consensus EPS by $0.03 but held near its 52-week high at $14.97. Insider sales totaling over $650,000 were tax-related, while analyst targets now range up to $17, creating a gap between the $11.86 average target and the stock price.
Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Source: tickerreport.com · themarketsdaily.com
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Safe Pro Group reported a quarterly EPS of -$0.15, one cent below consensus, but shares soared 37.7% on 21x average volume. The move pushed market cap to $128.89M even as negative net margin widened to 800.91%.
Source: MarketBeat · themarketsdaily.com
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
